Cumberland Pharmaceuticals
CPIX
33 hedge funds and large institutions have $38.3M invested in Cumberland Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 3 closing their positions.
0.1% more ownership
Funds ownership: 34% → 34.1% (+0.1%)
0% more capital invested
Capital invested by funds: $38.3M → $38.3M ($0)
3% less funds holding
Funds holding: 34 → 33 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.13M |
| 2 |
Renaissance Technologies
New York
|
+$174K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$128K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$52.4K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$40.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$617K |
| 2 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$369K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$167K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$142K |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
-$132K |
CPIX Hedge Fund Activity: Q3 2017 in Review
33 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2017, worth a combined $38.3M — unchanged from a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CPIX and 2 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 8 added.
The largest buyer was Stonepine Capital Management, adding an estimated $1.13M. The largest seller was Ariel Investments, cutting an estimated $617K.
- 33 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2017, down from 34 in Q2 2017.
- Funds reported $38.3M of Cumberland Pharmaceuticals stock for Q3 2017, unchanged quarter-over-quarter.
- 2 funds opened new Cumberland Pharmaceuticals positions in Q3 2017 and 3 closed out, a net change of -1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q3 2017 was Stonepine Capital Management, an estimated $1.13M added.
- The largest Cumberland Pharmaceuticals seller in Q3 2017 was Ariel Investments, an estimated $617K sold.
Based on aggregated 13F filings for Q3 2017.